Rocbrutinib,(LP-168, Hansoh Pharma (Lianyungang, Jiangsu, China) and Lupeng Pharma (Guangzhou, Guangdong, China) is a selective next-generation BTKi that irreversibly targets wild-type BTK, reversibly targets C481 mutant BTK (C481S, C481F, and C481R), and irreversibly targets other non-C481 mutations, such as the GM T474I, with preclinical activity in C481 and T474 mutants and clinical activity in RR CLL. Here, BTK is linked to B-cell chronic lymphocytic leukemia.